A double‐blind, randomized, placebo and positive‐controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin-Reference-Cited by-同舟云学术

A double‐blind, randomized, placebo and positive‐controlled study in healthy volunteers to evaluate pharmacokinetic and pharmacodynamic properties of multiple oral doses of cetagliptin

Published:2022-02-04 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Lu Jinmiao¹²^ORCID,Wang Lu³,Zhou Sufeng³,Zhou Chen³,Xie Lijun³,Chen Juan³,Tang Dong²,Tian Xusheng²,Xie Daosheng⁴,Ding Juping²,Wang Tong²,Yu Qiang²,Ding Jinsong¹,Shao Feng³

Affiliation:

1. Xiangya School of Pharmaceutical Sciences Central South University Changsha Hunan China

2. CGeneTech (Suzhou, China) Co., Ltd Suzhou Jiangsu China

3. Phase I Clinical Trial Unit The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China

4. Beijing noahpharm Medical Technology Co., Ltd Beijing China

Funder

National Science and Technology Major Project

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15209

Reference22 articles.

1. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study

2. Global Prevalence of Diabetes

3. Dipeptidyl Peptidase‐IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus;Rajput R;JIACM,2009

4. Gut peptides and type 2 diabetes mellitus treatment

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in small-molecule insulin secretagogues for diabetes treatment;Biomedicine & Pharmacotherapy;2024-09

2. Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modeling of cetagliptin in patients with type 2 diabetes mellitus;Frontiers in Endocrinology;2024-03-11

3. A randomized, double‐blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy;Diabetes, Obesity and Metabolism;2023-09-19

4. Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial;Diabetes, Obesity and Metabolism;2023-09-03

5. Tirzepatide: A Systematic Update;International Journal of Molecular Sciences;2022-11-23